<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26966328</article-id><article-id pub-id-type="pmc">4773935</article-id><article-id pub-id-type="publisher-id">BLT.15.164384</article-id><article-id pub-id-type="doi">10.2471/BLT.15.164384</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">&#x000c9;valuation des m&#x000e9;thodes GLOBOCAN pour &#x000e9;tablir des estimations nationales de l'incidence du cancer</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Una evaluaci&#x000f3;n de los m&#x000e9;todos GLOBOCAN para obtener estimaciones nacionales de la incidencia de c&#x000e1;ncer</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00627;&#x00643;&#x0062a;&#x00634;&#x00627;&#x00641; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; GLOBOCAN &#x00644;&#x00644;&#x0062e;&#x00631;&#x00648;&#x0062c; &#x00628;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00644;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00639;&#x00644;&#x00649; &#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644;&#x00629; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x08bc4;&#x04f30;&#x000a0;GLOBOCAN&#x000a0;&#x065b9;&#x06cd5;&#x0ff0c;&#x05f97;&#x051fa;&#x056fd;&#x05bb6;&#x0764c;&#x075c7;&#x053d1;&#x075c5;&#x07387;&#x04f30;&#x08ba1;&#x0503c;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432; GLOBOCAN, &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x0044f;&#x00435;&#x0043c;&#x0044b;&#x00445; &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x0043e;&#x00432; &#x0043f;&#x0043e; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x0043c;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Sebastien Antoni et al.</alt-title><alt-title alt-title-type="title-running-head">National estimates of cancer incidence</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Antoni</surname><given-names>Sebastien</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Soerjomataram</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>M&#x000f8;ller</surname><given-names>Bj&#x000f8;rn</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bray</surname><given-names>Freddie</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferlay</surname><given-names>Jacques</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon, Cedex 08, <country>France</country>.</aff><aff id="aff2"><label>b</label>Cancer Registry of Norway, Oslo, <country>Norway</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Sebastien Antoni (email: <email xlink:href="antonis@iarc.fr">antonis@iarc.fr</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>1</month><year>2016</year></pub-date><volume>94</volume><issue>3</issue><fpage>174</fpage><lpage>184</lpage><history><date date-type="received"><day>16</day><month>9</month><year>2015</year></date><date date-type="rev-recd"><day>25</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2016 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To assess the validity of the GLOBOCAN methods for deriving national estimates of cancer incidence.</p></sec><sec><title>Methods</title><p>We obtained incidence and mortality data from Norway by region, year of diagnosis, cancer site, sex and 5-year age group for the period 1983&#x02013;2012 from the NORDCAN database. Estimates for the year 2010 were derived using nine different methods from GLOBOCAN. These included the projection of national historical rates, the use of regional proxies and the combination of national mortality data with mortality to incidence ratios or relative survival proportions. We then compared the national estimates with recorded cancer incidence data.</p></sec><sec><title>Findings</title><p>Differences between the estimates derived using different methods varied by cancer site and sex. Methods based on projections performed better where major changes in recent trends were absent. Methods based on mortality data performed less well for cancers associated with small numbers of deaths and for cancers detectable by screening. In countries with longstanding cancer registries of high quality, regional-based, or trends-based incidence estimates perform reasonably well in comparison with recorded incidence.</p></sec><sec><title>Conclusion</title><p>Although the performance of the GLOBOCAN methods varies by cancer site and sex in this study, the results emphasize a need for more high-quality population-based cancer registries &#x02013; either regional or, where practical and feasible, national registries &#x02013; to describe cancer patterns and trends for planning cancer control priorities.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>&#x000c9;valuer la validit&#x000e9; des m&#x000e9;thodes GLOBOCAN pour &#x000e9;tablir des estimations nationales de l'incidence du cancer.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons recueilli les donn&#x000e9;es de la Norv&#x000e8;ge sur l'incidence et la mortalit&#x000e9; par r&#x000e9;gion, ann&#x000e9;e de diagnostic, si&#x000e8;ge du cancer, sexe et tranche d'&#x000e2;ge de 5 ans pour la p&#x000e9;riode 1983&#x02013;2012 dans la base de donn&#x000e9;es NORDCAN. Les estimations pour l'ann&#x000e9;e 2010 ont &#x000e9;t&#x000e9; &#x000e9;tablies suivant neuf m&#x000e9;thodes GLOBOCAN diff&#x000e9;rentes, dont l'extrapolation &#x000e0; partir de taux nationaux pass&#x000e9;s, l'utilisation d'indicateurs r&#x000e9;gionaux et la combinaison de donn&#x000e9;es nationales sur la mortalit&#x000e9; aux rapports mortalit&#x000e9;/incidence ou aux taux de survie relatifs. Nous avons ensuite compar&#x000e9; les estimations nationales aux donn&#x000e9;es enregistr&#x000e9;es sur l'incidence du cancer.</p></sec><sec><title>R&#x000e9;sultats</title><p>Les estimations obtenues suivant diff&#x000e9;rentes m&#x000e9;thodes variaient selon le si&#x000e8;ge du cancer et le sexe. Les m&#x000e9;thodes consistant en une extrapolation donnaient de meilleurs r&#x000e9;sultats en l'absence de changement majeur des tendances r&#x000e9;centes. Les m&#x000e9;thodes utilisant les donn&#x000e9;es sur la mortalit&#x000e9; s'av&#x000e9;raient moins fiables pour les cancers associ&#x000e9;s &#x000e0; un faible nombre de d&#x000e9;c&#x000e8;s et les cancers d&#x000e9;tectables par d&#x000e9;pistage. Dans les pays qui tenaient depuis longtemps des registres du cancer de qualit&#x000e9;, les estimations de l'incidence d'apr&#x000e8;s les indicateurs r&#x000e9;gionaux ou les tendances &#x000e9;taient plut&#x000f4;t fiables par rapport &#x000e0; l'incidence enregistr&#x000e9;e.</p></sec><sec><title>Conclusion</title><p>Bien que, dans cette &#x000e9;tude, la fiabilit&#x000e9; des m&#x000e9;thodes GLOBOCAN varie selon le si&#x000e8;ge du cancer et le sexe, les r&#x000e9;sultats r&#x000e9;v&#x000e8;lent la n&#x000e9;cessit&#x000e9; de tenir davantage de registres du cancer de qualit&#x000e9; &#x02013; registres r&#x000e9;gionaux ou, lorsque cela est faisable, nationaux &#x02013; afin de d&#x000e9;crire les profils et tendances en mati&#x000e8;re de cancer et de planifier les priorit&#x000e9;s de lutte contre cette maladie.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Evaluar la validez de los m&#x000e9;todos GLOBOCAN para obtener estimaciones nacionales de la incidencia de c&#x000e1;ncer.</p></sec><sec><title>M&#x000e9;todos</title><p>Se obtuvieron datos sobre la incidencia y mortalidad en Noruega por regiones, a&#x000f1;o de diagn&#x000f3;stico, localizaci&#x000f3;n del c&#x000e1;ncer, sexo y grupos de edades de cinco a&#x000f1;os durante el periodo comprendido entre 1983 y 2012 de la base de datos NORDCAN. Las estimaciones del a&#x000f1;o 2010 se obtuvieron utilizando nueve m&#x000e9;todos diferentes de GLOBOCAN. Entre ellos se encontraban la proyecci&#x000f3;n de tasas nacionales hist&#x000f3;ricas, el uso de indicadores regionales y la combinaci&#x000f3;n de datos de mortalidad nacionales con coeficientes de incidencia o porcentajes de supervivencia relativos. Posteriormente, se compararon las estimaciones nacionales con los datos de incidencia de c&#x000e1;ncer registrados.</p></sec><sec><title>Resultados</title><p>Las diferencias entre las estimaciones obtenidas utilizando distintos m&#x000e9;todos variaron seg&#x000fa;n la localizaci&#x000f3;n del c&#x000e1;ncer y el sexo. Los m&#x000e9;todos basados en las proyecciones mostraron mejores resultados cuando se observ&#x000f3; una ausencia de cambios importantes en las &#x000fa;ltimas tendencias. Los m&#x000e9;todos basados en los datos de mortalidad obtuvieron peores resultados en relaci&#x000f3;n con los c&#x000e1;nceres asociados a un menor n&#x000fa;mero de fallecimientos y con los c&#x000e1;nceres detectables en revisiones. En los pa&#x000ed;ses con registros de c&#x000e1;ncer prolongados de alta calidad, las estimaciones de incidencia por regiones o por tendencias muestran resultados razonablemente buenos, en comparaci&#x000f3;n con las incidencias registradas.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>A pesar de que en este estudio el rendimiento de los m&#x000e9;todos GLOBOCAN var&#x000ed;a seg&#x000fa;n la localizaci&#x000f3;n del c&#x000e1;ncer y el sexo, los resultados destacan la necesidad de obtener registros de c&#x000e1;ncer de mejor calidad y basados en la poblaci&#x000f3;n (ya sea a nivel regional o, cuando proceda, a nivel nacional) para describir los patrones y tendencias del c&#x000e1;ncer para planificar las prioridades para controlarlo.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00645;&#x0062f;&#x00649; &#x00635;&#x0062d;&#x00629; &#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00627;&#x00643;&#x0062a;&#x00634;&#x00627;&#x00641; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; GLOBOCAN &#x00644;&#x00644;&#x0062e;&#x00631;&#x00648;&#x0062c; &#x00628;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00644;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00639;&#x00644;&#x00649; &#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x00628;&#x00644;&#x00627;&#x0062f;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00644;&#x00642;&#x0062f; &#x0062d;&#x00635;&#x00644;&#x00646;&#x00627; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x00644;&#x00642;&#x00629; &#x00628;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00648;&#x00627;&#x00644;&#x00648;&#x00641;&#x0064a;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00646;&#x00631;&#x00648;&#x0064a;&#x0062c; &#x0062d;&#x00633;&#x00628; &#x00627;&#x00644;&#x00645;&#x00646;&#x00637;&#x00642;&#x00629; &#x00648;&#x00633;&#x00646;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00648;&#x00645;&#x00648;&#x00642;&#x00639; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00648;&#x00627;&#x00644;&#x0062c;&#x00646;&#x00633; &#x00648;&#x00641;&#x00626;&#x00627;&#x0062a; &#x00639;&#x00645;&#x00631;&#x0064a;&#x00629; &#x00645;&#x00646; 5 &#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00645;&#x00646; &#x00639;&#x00627;&#x00645; 1983 &#x00625;&#x00644;&#x00649; &#x00639;&#x00627;&#x00645; 2012 &#x00645;&#x00646; &#x00642;&#x00627;&#x00639;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; NORDCAN. &#x00648;&#x00643;&#x00627;&#x00646;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062e;&#x00627;&#x00635;&#x00629; &#x00628;&#x00639;&#x00627;&#x00645; 2010 &#x00645;&#x00634;&#x0062a;&#x00642;&#x00629; &#x00645;&#x00646; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x0062a;&#x00633;&#x00639; &#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x00629; &#x00645;&#x00646; &#x00645;&#x00634;&#x00631;&#x00648;&#x00639; GLOBOCAN. &#x00648;&#x0062a;&#x00636;&#x00645;&#x00646;&#x0062a; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x00639;&#x0062f;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00631;&#x0064a;&#x0062e;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00648;&#x00637;&#x00646;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00639;&#x00627;&#x00646;&#x00629; &#x00628;&#x00648;&#x00643;&#x00644;&#x00627;&#x00621; &#x00625;&#x00642;&#x00644;&#x0064a;&#x00645;&#x0064a;&#x0064a;&#x00646;&#x0060c; &#x00648;&#x00627;&#x00644;&#x0062c;&#x00645;&#x00639; &#x00628;&#x0064a;&#x00646; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00641;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00637;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00639; &#x00646;&#x00633;&#x00628; &#x00627;&#x00644;&#x00648;&#x00641;&#x0064a;&#x00627;&#x0062a; &#x0062c;&#x00631;&#x00627;&#x00621; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00623;&#x00648; &#x00646;&#x00633;&#x00628; &#x00627;&#x00644;&#x00628;&#x00642;&#x00627;&#x00621; &#x00639;&#x00644;&#x00649; &#x00642;&#x0064a;&#x0062f; &#x00627;&#x00644;&#x0062d;&#x0064a;&#x00627;&#x00629; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a;&#x00629;. &#x00648;&#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00639;&#x0062f; &#x00630;&#x00644;&#x00643; &#x00628;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00637;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00639; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062c;&#x00644;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x0062a;&#x00628;&#x00627;&#x0064a;&#x00646;&#x0062a; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00644;&#x00627;&#x00641;&#x00627;&#x0062a; &#x00645;&#x00627; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00634;&#x0062a;&#x00642;&#x00629; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x00629; &#x0062d;&#x00633;&#x00628; &#x00645;&#x00648;&#x00642;&#x00639; &#x0062d;&#x0062f;&#x00648;&#x0062b; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00648;&#x0062c;&#x00646;&#x00633; &#x00627;&#x00644;&#x00645;&#x00631;&#x0064a;&#x00636;. &#x00648;&#x00643;&#x00627;&#x00646; &#x00623;&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0062f;&#x00629; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00642;&#x00639;&#x00627;&#x0062a; &#x00623;&#x00641;&#x00636;&#x00644; &#x00641;&#x0064a; &#x00638;&#x00644; &#x0063a;&#x0064a;&#x00627;&#x00628; &#x00623;&#x0064a; &#x0062a;&#x0063a;&#x0064a;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00643;&#x00628;&#x0064a;&#x00631;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00646;&#x00632;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x0062f;&#x0064a;&#x0062b;&#x00629;. &#x00623;&#x00645;&#x00627; &#x00623;&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00646;&#x0062f;&#x00629; &#x00625;&#x00644;&#x00649; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00641;&#x0064a;&#x00627;&#x0062a; &#x00641;&#x00642;&#x0062f; &#x00643;&#x00627;&#x00646; &#x00623;&#x00642;&#x00644; &#x0062c;&#x00648;&#x0062f;&#x00629; &#x00644;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00623;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00645;&#x0062a;&#x0062f;&#x00646;&#x0064a;&#x00629; &#x00644;&#x00644;&#x00648;&#x00641;&#x00627;&#x00629; &#x00648;&#x00628;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0064a;&#x00645;&#x00643;&#x00646; &#x00627;&#x00643;&#x0062a;&#x00634;&#x00627;&#x00641;&#x00647;&#x00627; &#x00645;&#x00646; &#x0062e;&#x00644;&#x00627;&#x00644; &#x00627;&#x00644;&#x00641;&#x0062d;&#x00635;. &#x00641;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0064a;&#x00648;&#x0062c;&#x0062f; &#x00644;&#x0062f;&#x0064a;&#x00647;&#x00627; &#x00633;&#x0062c;&#x00644;&#x00627;&#x0062a; &#x00644;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00637;&#x00648;&#x0064a;&#x00644;&#x00629; &#x00627;&#x00644;&#x00623;&#x00645;&#x0062f; &#x00648;&#x0062a;&#x00642;&#x00648;&#x00645; &#x00628;&#x00631;&#x00635;&#x0062f; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x0062f;&#x00642;&#x00629; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00639;&#x00644;&#x00649; &#x00623;&#x00633;&#x00627;&#x00633; &#x00625;&#x00642;&#x00644;&#x0064a;&#x00645;&#x0064a; &#x00623;&#x00648; &#x00648;&#x00641;&#x00642;&#x0064b;&#x00627; &#x00644;&#x00644;&#x00646;&#x00632;&#x00639;&#x00627;&#x0062a;&#x0060c; &#x0062a;&#x00633;&#x0064a;&#x00631; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00648;&#x00641;&#x00642;&#x0064b;&#x00627; &#x00644;&#x00623;&#x00633;&#x00633; &#x00645;&#x00646;&#x00637;&#x00642;&#x0064a;&#x00629; &#x00628;&#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00645;&#x00639; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062c;&#x00644;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00631;&#x0063a;&#x00645; &#x00645;&#x00646; &#x00623;&#x00646; &#x00623;&#x0062f;&#x00627;&#x00621; &#x00648;&#x00633;&#x00627;&#x00626;&#x00644; &#x00627;&#x00643;&#x0062a;&#x00634;&#x00627;&#x00641; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; GLOBOCAN &#x0064a;&#x0062a;&#x00628;&#x00627;&#x0064a;&#x00646; &#x0062d;&#x00633;&#x00628; &#x00645;&#x00648;&#x00642;&#x00639; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00648;&#x0062c;&#x00646;&#x00633; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628; &#x00641;&#x0064a; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629;&#x0060c; &#x0062a;&#x00624;&#x00643;&#x0062f; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062d;&#x00627;&#x0062c;&#x00629; &#x00625;&#x00644;&#x00649; &#x00625;&#x00642;&#x00627;&#x00645;&#x00629; &#x00633;&#x0062c;&#x00644;&#x00627;&#x0062a; &#x00644;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00628;&#x0062f;&#x00642;&#x00629; &#x00623;&#x00643;&#x00628;&#x00631; &#x00648;&#x00642;&#x00627;&#x00626;&#x00645;&#x00629; &#x00639;&#x00644;&#x00649; &#x00642;&#x00637;&#x00627;&#x00639; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; <styled-content style-type="direction" style="direction:ltr;">&#x02013; </styled-content>&#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x0064a;&#x00645;&#x00643;&#x00646; &#x00623;&#x00646; &#x0062a;&#x00643;&#x00648;&#x00646; &#x00633;&#x0062c;&#x00644;&#x00627;&#x0062a; &#x00625;&#x00642;&#x00644;&#x0064a;&#x00645;&#x0064a;&#x00629; &#x00623;&#x00648; &#x00648;&#x00637;&#x00646;&#x0064a;&#x00629; (&#x00625;&#x00630;&#x00627; &#x00645;&#x00627; &#x0062a;&#x00648;&#x00641;&#x00631;&#x0062a; &#x00625;&#x00645;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00639;&#x00645;&#x00644;&#x0064a;&#x00629; &#x00648;&#x00642;&#x00627;&#x00628;&#x00644;&#x00629; &#x00644;&#x00644;&#x0062a;&#x00637;&#x00628;&#x0064a;&#x00642; &#x00644;&#x00625;&#x00642;&#x00627;&#x00645;&#x00629; &#x0062a;&#x00644;&#x00643; &#x00627;&#x00644;&#x00633;&#x0062c;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00648;&#x00637;&#x00646;&#x0064a;&#x00629;) <styled-content style-type="direction" style="direction:ltr;">&#x02013; </styled-content>&#x00648;&#x00630;&#x00644;&#x00643; &#x00644;&#x00648;&#x00635;&#x00641; &#x00623;&#x00646;&#x00645;&#x00627;&#x00637; &#x00648;&#x00646;&#x00632;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00644;&#x00643;&#x0064a; &#x0064a;&#x0062a;&#x00645; &#x00648;&#x00636;&#x00639; &#x00627;&#x00644;&#x0062a;&#x0062e;&#x00637;&#x0064a;&#x00637; &#x00627;&#x00644;&#x00644;&#x00627;&#x00632;&#x00645; &#x00644;&#x00623;&#x00648;&#x00644;&#x00648;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00637;&#x00631;&#x00629; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x065e8;&#x05728;&#x08bc4;&#x04f30;&#x000a0;GLOBOCAN&#x000a0;&#x065b9;&#x06cd5;&#x07684;&#x06709;&#x06548;&#x06027;&#x0ff0c;&#x04ece;&#x0800c;&#x05f97;&#x051fa;&#x056fd;&#x05bb6;&#x0764c;&#x075c7;&#x053d1;&#x075c5;&#x07387;&#x04f30;&#x08ba1;&#x0503c;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x04ece;&#x000a0;NORDCAN&#x000a0;&#x06570;&#x0636e;&#x05e93;&#x04e2d;&#x0ff0c;&#x083b7;&#x05f97;&#x000a0;1983&#x02013;2012&#x000a0;&#x05e74;&#x095f4;&#x0632a;&#x05a01;&#x04e0d;&#x0540c;&#x05730;&#x0533a;&#x03001;&#x08bca;&#x065ad;&#x05e74;&#x04efd;&#x03001;&#x0764c;&#x075c7;&#x090e8;&#x04f4d;&#x03001;&#x06027;&#x0522b;&#x04ee5;&#x053ca;&#x000a0;5&#x000a0;&#x05c81;&#x05e74;&#x09f84;&#x06bb5;&#x07684;&#x053d1;&#x075c5;&#x07387;&#x0548c;&#x06b7b;&#x04ea1;&#x07387;&#x06570;&#x0636e;&#x03002;&#x091c7;&#x07528;&#x04e86;&#x000a0;9&#x000a0;&#x079cd;&#x04e0d;&#x0540c;&#x07684;&#x000a0;GLOBOCAN&#x000a0;&#x065b9;&#x06cd5;&#x0ff0c;&#x05f97;&#x051fa;&#x000a0;2010&#x000a0;&#x05e74;&#x04f30;&#x08ba1;&#x0503c;&#x03002;&#x08fd9;&#x04e9b;&#x065b9;&#x06cd5;&#x05305;&#x062ec;&#x063a8;&#x065ad;&#x056fd;&#x05bb6;&#x05386;&#x053f2;&#x06bd4;&#x07387;&#x03001;&#x04f7f;&#x07528;&#x05730;&#x0533a;&#x04ee3;&#x08868;&#x0793a;&#x04f8b;&#x04ee5;&#x053ca;&#x07ed3;&#x05408;&#x056fd;&#x05bb6;&#x06b7b;&#x04ea1;&#x07387;&#x06570;&#x0636e;&#x0548c;&#x06b7b;&#x04ea1;&#x07387;&#x04e0e;&#x053d1;&#x075c5;&#x07387;&#x07684;&#x06bd4;&#x04f8b;&#x06216;&#x076f8;&#x05bf9;&#x0751f;&#x05b58;&#x06bd4;&#x04f8b;&#x03002;&#x06211;&#x04eec;&#x0968f;&#x0540e;&#x05c06;&#x056fd;&#x05bb6;&#x04f30;&#x08ba1;&#x0503c;&#x0548c;&#x08bb0;&#x05f55;&#x07684;&#x0764c;&#x075c7;&#x053d1;&#x075c5;&#x07387;&#x06570;&#x0636e;&#x08fdb;&#x0884c;&#x06bd4;&#x08f83;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x091c7;&#x07528;&#x056e0;&#x0764c;&#x075c7;&#x090e8;&#x04f4d;&#x0548c;&#x06027;&#x0522b;&#x0800c;&#x04e0d;&#x0540c;&#x07684;&#x065b9;&#x06cd5;&#x05f97;&#x051fa;&#x07684;&#x04f30;&#x08ba1;&#x0503c;&#x04e4b;&#x095f4;&#x04e5f;&#x06709;&#x06240;&#x05dee;&#x05f02;&#x03002;&#x05982;&#x0679c;&#x08fd1;&#x0671f;&#x08d8b;&#x052bf;&#x04e2d;&#x04e0d;&#x05b58;&#x05728;&#x04e3b;&#x08981;&#x053d8;&#x05316;&#x0ff0c;&#x057fa;&#x04e8e;&#x063a8;&#x065ad;&#x07684;&#x065b9;&#x06cd5;&#x05219;&#x066f4;&#x06709;&#x06548;&#x03002;&#x09488;&#x05bf9;&#x06b7b;&#x04ea1;&#x07387;&#x04f4e;&#x07684;&#x0764c;&#x075c7;&#x06216;&#x0901a;&#x08fc7;&#x07b5b;&#x067e5;&#x053ef;&#x068c0;&#x06d4b;&#x051fa;&#x07684;&#x0764c;&#x075c7;&#x0ff0c;&#x091c7;&#x07528;&#x057fa;&#x04e8e;&#x06b7b;&#x04ea1;&#x07387;&#x06570;&#x0636e;&#x07684;&#x065b9;&#x06cd5;&#x06548;&#x0679c;&#x04e0d;&#x04f73;&#x03002;&#x05728;&#x04e00;&#x04e9b;&#x056fd;&#x05bb6;&#x0ff0c;&#x076f8;&#x05bf9;&#x04e8e;&#x08bb0;&#x05f55;&#x07684;&#x053d1;&#x075c5;&#x07387;&#x0ff0c;&#x0901a;&#x08fc7;&#x0957f;&#x0671f;&#x09ad8;&#x08d28;&#x091cf;&#x07684;&#x0764c;&#x075c7;&#x0767b;&#x08bb0;&#x0ff0c;&#x057fa;&#x04e8e;&#x05730;&#x0533a;&#x06216;&#x057fa;&#x04e8e;&#x08d8b;&#x052bf;&#x07684;&#x053d1;&#x075c5;&#x07387;&#x04f30;&#x08ba1;&#x0503c;&#x06548;&#x0679c;&#x076f8;&#x05f53;&#x0597d;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x05c3d;&#x07ba1;&#x05728;&#x0672c;&#x07814;&#x07a76;&#x04e2d;&#x0ff0c;GLOBOCAN&#x000a0;&#x065b9;&#x06cd5;&#x07684;&#x06548;&#x0679c;&#x056e0;&#x0764c;&#x075c7;&#x090e8;&#x04f4d;&#x0548c;&#x06027;&#x0522b;&#x0800c;&#x05f02;&#x0ff0c;&#x04f46;&#x0662f;&#x07ed3;&#x0679c;&#x08868;&#x0660e;&#x04e3a;&#x063cf;&#x08ff0;&#x0764c;&#x075c7;&#x07c7b;&#x0578b;&#x0548c;&#x08d8b;&#x052bf;&#x0ff0c;&#x04ee5;&#x0786e;&#x05b9a;&#x0764c;&#x075c7;&#x063a7;&#x05236;&#x05de5;&#x04f5c;&#x091cd;&#x070b9;&#x0ff0c;&#x057fa;&#x04e8e;&#x04eba;&#x07fa4;&#x07684;&#x066f4;&#x09ad8;&#x08d28;&#x091cf;&#x0764c;&#x075c7;&#x0767b;&#x08bb0;&#x0591a;&#x0591a;&#x076ca;&#x05584;&#x03002;&#x08fd9;&#x04e9b;&#x0767b;&#x08bb0;&#x053ef;&#x04ee5;&#x0662f;&#x05730;&#x0533a;&#x0767b;&#x08bb0;&#x04e5f;&#x053ef;&#x04ee5;&#x0662f;&#x05b9e;&#x07528;&#x04e14;&#x053ef;&#x0884c;&#x07684;&#x056fd;&#x05bb6;&#x0767b;&#x08bb0;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435; </title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x00438;&#x00433;&#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432; GLOBOCAN &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x0043e;&#x00432; &#x0043f;&#x0043e; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x0043c;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00412; &#x0041d;&#x0043e;&#x00440;&#x00432;&#x00435;&#x00433;&#x00438;&#x00438; &#x00438;&#x00437; &#x00431;&#x00430;&#x00437;&#x0044b; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; NORDCAN &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0044b; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00438; &#x00441;&#x0043c;&#x00435;&#x00440;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;, &#x0043e;&#x00442;&#x00441;&#x0043e;&#x00440;&#x00442;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043f;&#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00443;, &#x00433;&#x0043e;&#x00434;&#x00443; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, &#x00437;&#x00430;&#x00442;&#x00440;&#x0043e;&#x0043d;&#x00443;&#x00442;&#x0043e;&#x0043c;&#x00443; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00443;, &#x0043f;&#x0043e;&#x0043b;&#x00443; &#x00438; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x0043d;&#x0044b;&#x0043c; &#x00433;&#x00440;&#x00443;&#x0043f;&#x0043f;&#x00430;&#x0043c; &#x00432; 5-&#x0043b;&#x00435;&#x00442;&#x0043d;&#x00435;&#x00439; &#x00440;&#x00430;&#x00437;&#x00431;&#x00438;&#x00432;&#x0043a;&#x00435;, &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x0044f;&#x00449;&#x00438;&#x00435;&#x00441;&#x0044f; &#x0043a; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434;&#x00443; 1983&#x02013;2012 &#x00433;&#x00433;. &#x0041f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x0044b; &#x0043d;&#x00430; 2010 &#x00433;&#x0043e;&#x00434; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0044b; &#x00441; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; &#x00434;&#x00435;&#x00432;&#x0044f;&#x00442;&#x00438; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00445; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x00438;&#x00437; &#x00431;&#x00430;&#x00437;&#x0044b; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; GLOBOCAN. &#x00412; &#x00438;&#x00445; &#x00447;&#x00438;&#x00441;&#x0043b;&#x0043e; &#x00432;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00435;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x00441;&#x00442;&#x0043e;&#x00440;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439;, &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x0043f;&#x00440;&#x00438;&#x00431;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439; &#x0043f;&#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00443; &#x00438; &#x0043e;&#x00431;&#x0044a;&#x00435;&#x00434;&#x00438;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043e; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x00441;&#x0043c;&#x00435;&#x00440;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00441;&#x0043e; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;&#x0043c;&#x00438; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00448;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043c;&#x00435;&#x00440;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043a; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00438;&#x0043b;&#x00438; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x0043c;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x0043f;&#x0043e;&#x00440;&#x00446;&#x00438;&#x0044f;&#x0043c;&#x00438; &#x00432;&#x0044b;&#x00436;&#x00438;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438;. &#x00417;&#x00430;&#x00442;&#x00435;&#x0043c; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x0043e; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x0043e;&#x00432; &#x00441; &#x00437;&#x00430;&#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x0043c;&#x00438; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x0043c;&#x00438; &#x0043e; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x0043c;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x0041f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x0044b;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00441; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; &#x00440;&#x00430;&#x00437;&#x0043d;&#x0044b;&#x00445; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432;, &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x00430;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00432; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043e;&#x00442; &#x0043f;&#x0043e;&#x00440;&#x00430;&#x00436;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00430; &#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00430; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x00430;. &#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b; &#x0043d;&#x00430; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00435;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x0043e;&#x00437;&#x00432;&#x0043e;&#x0043b;&#x00438;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x00442;&#x0044c; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x00442;&#x0043e;&#x00447;&#x0043d;&#x0044b;&#x00435; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435;, &#x00435;&#x00441;&#x0043b;&#x00438; &#x00432; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043d;&#x00438;&#x00445; &#x00442;&#x00435;&#x0043d;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00438;&#x0044f;&#x00445; &#x0043e;&#x00442;&#x00441;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x00438;&#x00437;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;, &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043d;&#x00430; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043e; &#x00441;&#x0043c;&#x00435;&#x00440;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;, &#x0043f;&#x0043e;&#x00437;&#x00432;&#x0043e;&#x0043b;&#x00438;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x00442;&#x0044c; &#x0043c;&#x00435;&#x0043d;&#x00435;&#x00435; &#x00442;&#x0043e;&#x00447;&#x0043d;&#x0044b;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x0044b; &#x00434;&#x0043b;&#x0044f; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x0043c;, &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00441; &#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00438;&#x0043c; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e;&#x0043c; &#x0043b;&#x00435;&#x00442;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0043e;&#x00432;, &#x00438; &#x00434;&#x0043b;&#x0044f; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, &#x0043a;&#x0043e;&#x00433;&#x00434;&#x00430; &#x00440;&#x00430;&#x0043a; &#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x00438;&#x00442;&#x0044c; &#x00441; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00449;&#x0044c;&#x0044e; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;. &#x00412; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00432; &#x00442;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00434;&#x0043b;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00432;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x00438; &#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00442; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x0043e;&#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00440;&#x00435;&#x00435;&#x00441;&#x00442;&#x00440;&#x0044b; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x00432;&#x0044b;&#x00445; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;, &#x0043f;&#x00440;&#x0043e;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043d;&#x00430; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00438; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x0043b;&#x00438; &#x00442;&#x00435;&#x0043d;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00439; &#x0043f;&#x0043e;&#x00437;&#x00432;&#x0043e;&#x0043b;&#x0044f;&#x0043b;&#x0043e; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x00442;&#x0044c; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x00438;&#x0043b;&#x00438; &#x0043c;&#x00435;&#x0043d;&#x00435;&#x00435; &#x00430;&#x00434;&#x00435;&#x0043a;&#x00432;&#x00430;&#x00442;&#x0043d;&#x0044b;&#x00435; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00438; &#x0043f;&#x0043e; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x00441; &#x00437;&#x00430;&#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c;&#x0044e;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00425;&#x0043e;&#x00442;&#x0044f; &#x00432; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x0043c; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00438; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432; GLOBOCAN &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00432; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043e;&#x00442; &#x0043f;&#x0043e;&#x00440;&#x00430;&#x00436;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00430; &#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00430; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x00430;, &#x00435;&#x00433;&#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b; &#x00441;&#x00432;&#x00438;&#x00434;&#x00435;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00442; &#x0043e; &#x0043d;&#x00435;&#x0043e;&#x00431;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00432; &#x00434;&#x0043e;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x0043e;&#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00435;&#x00435;&#x00441;&#x00442;&#x00440;&#x00430;&#x00445; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x00432;&#x0044b;&#x00445; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x0043c; &#x00438;&#x0043b;&#x00438;, &#x00435;&#x00441;&#x0043b;&#x00438; &#x0044d;&#x00442;&#x0043e; &#x00446;&#x00435;&#x0043b;&#x00435;&#x00441;&#x0043e;&#x0043e;&#x00431;&#x00440;&#x00430;&#x00437;&#x0043d;&#x0043e; &#x00438; &#x0043f;&#x00440;&#x00430;&#x0043a;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438; &#x0043e;&#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x00438;&#x0043c;&#x0043e;, &#x0043d;&#x00430; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x0043c; &#x00443;&#x00440;&#x0043e;&#x00432;&#x0043d;&#x00435;, &#x00447;&#x00442;&#x0043e;&#x00431;&#x0044b; &#x0043e;&#x0043f;&#x00438;&#x00441;&#x00430;&#x00442;&#x0044c; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438; &#x00438; &#x00442;&#x00435;&#x0043d;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00438; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x00432;&#x0044b;&#x00445; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x00438;&#x0043e;&#x00440;&#x00438;&#x00442;&#x00435;&#x00442;&#x0043e;&#x00432; &#x00432; &#x00431;&#x0043e;&#x00440;&#x0044c;&#x00431;&#x00435; &#x00441; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x0043c;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Cancer is among the most common causes of morbidity and mortality worldwide, with an estimated 14&#x000a0;million new cases and 8&#x000a0;million deaths in 2012, projected to rise by at least 70% by 2030.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Timely and accurate cancer statistics are crucial to identify priorities for cancer control strategies at the national level. Yet, only 34 of 194 World Health Organization (WHO) Member States presently report high-quality national mortality data,<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> while 68 countries provided high-quality incidence data for the last volume of <italic>Cancer incidence in five continents</italic>.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> As a result, many policy-makers rely on national cancer incidence and mortality estimates of variable precision to inform cancer control priorities.</p><p>GLOBOCAN, a project of the International Agency for Research on Cancer (IARC) provides estimates by cancer site and sex using the best available data in each country and several methods of estimation.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Producing high-quality estimates therefore requires a dual approach of improving the reported data (developing cancer registries and civil/vital registration systems) and a continual assessment of the validity of the estimation procedures to improve the methods used.</p><p>This study focuses on the validity of the methods used in GLOBOCAN to derive national cancer incidence estimates, based on a retrospective comparison of these estimates to the observed national data in a setting with high quality cancer registry data. Although we focused on the methods most commonly used in high-income countries, we also aimed at providing insights into the validity of the methods more broadly, including methods used more predominantly in low- and middle-income countries.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Recorded data</title><p>To validate the nine methods used in GLOBOCAN to estimate national incidence in 2012 (GLOBOCAN 2012), long-term national and regional incidence and mortality data as well as 5-year relative survival estimates are required. Of the few countries with such data available, we selected Norway because of the consistently high quality of its cancer registry data, available nationally and by region. Cancer reporting is a legal requirement in Norway and data linkage procedures with the cause of death registry further increase the completeness of the information. For the period 2001&#x02013;2005, data completeness was estimated at 98.8%, while 93.8% of the cases had been verified by examining biopsy samples under a microscope.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref></p><p>From the Nordic cancer database NORDCAN, we extracted Norwegian incidence and mortality data by region, year of diagnosis, cancer site, sex and 5-years age group (starting at 0&#x02013;4 and ending at 85+) for the period 1983&#x02013;2012.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> We also extracted Norwegian 5-year relative survival proportions for each cancer site as well as incidence and mortality data from neighbouring countries Denmark, Finland, Iceland and Sweden.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> As with GLOBOCAN 2012, national population data were obtained from the United Nations<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> while regional population data were extracted from NORDCAN.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>Cancer sites of the recorded cases and deaths were grouped by the codes in the <italic>International statistical classification of diseases and related health problems, 10th revision</italic> (ICD-10) to correspond to the sites used in GLOBOCAN. Unspecified neoplasms of the uterus (ICD-10 code C55) were reallocated to the cervix (C53) and corpus uteri (C54) according to the respective proportions of these two sites in the different datasets.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref></p><p>We computed the number of cases by sex and cancer site in Norway in 2010 as the average of the recorded cancer cases between 2009 and 2011 to define a gold standard for comparisons. We then applied each of the nine methods used in GLOBOCAN 2012 to estimate the number of cancer cases in Norway in 2010, by sex and cancer site, and compared these estimates with the gold standard.</p></sec><sec><title>Estimation methods</title><p>The GLOBOCAN methods are summarized in <xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>, together with the algorithm used to select them in GLOBOCAN based on the availability of data in each country. More details can be found elsewhere.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R8" ref-type="bibr"><sup>8</sup></xref>
<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> illustrates which method was used for each country within the GLOBOCAN 2012 project.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig.&#x000a0;1</label><caption><p>Method selection algorithm and the setting(s) in which methods were most commonly applied when estimating cancer incidence in GLOBOCAN 2012</p></caption><p>HDI: Human Development Index; M:I mortality:incidence.</p><p>Notes: For Method&#x000a0;1, two projections were done. Method&#x000a0;1A used NORDPRED (5-year intervals, &#x0003e;&#x02009;15 years of data) and method 1B used DEPPRED (annual, &#x0003c;&#x02009;10 years of data).</p><p>Method&#x000a0;2 also used for cancer sites with stabilizing rates following large temporal variations (for example due to screening). </p><p>Method&#x000a0;3 used M:I ratios from regional registries and method&#x000a0;4 used data from neighbouring countries. </p><p>Method&#x000a0;6 used rates from one registry and method&#x000a0;7 used weighted rates from multiple registries.</p><graphic xlink:href="BLT.15.164384-F1"/></fig><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig.&#x000a0;2</label><caption><p>Methods of national cancer incidence estimation used for 184 countries for the GLOBOCAN 2012 project</p></caption><graphic xlink:href="BLT.15.164384-F2"/></fig><p>The data required for each of the nine methods are summarized in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>.The methods used may produce under- or overestimates at different cancer sites. Therefore, presenting an overall number of cases based on the sum of site-specific numbers could be misleading, if aggregated overestimates and underestimates cancel each other out. We thus report separately the total number of cases underestimated and overestimated for each method. These were then aggregated to assess the differences between the results and the Norwegian recorded data.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><title>Required conditions for reliable estimations for each of the nine methods used to estimate cancer incidence in GLOBOCAN 2012</title></caption><table frame="hsides" rules="groups"><col width="53" span="1"/><col width="192" span="1"/><col width="409" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Method</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Data required to use the method</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Conditions required for reliable estimations</th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">1</td><td rowspan="2" valign="top" align="left" colspan="1">Historical national incidence data</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/population size</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Recent incidence trends continue into near future</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">2</td><td rowspan="2" valign="top" align="left" colspan="1">Recent national incidence data</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/population size</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Stable incidence rates in near future</td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">3</td><td rowspan="3" valign="top" align="left" colspan="1">National mortality data and M:I ratios from regional registries within the country</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/deaths</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Trends in incidence, mortality and survival are relatively stable over time</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Case fatality in combined regions representative nationally</td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">4</td><td rowspan="3" valign="top" align="left" colspan="1">National mortality data and M:I ratios from registries in neighbouring countries</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/deaths</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Trends in incidence, mortality and survival are relatively stable over time</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Case fatality in combined neighbouring countries representative nationally</td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1">5</td><td rowspan="3" valign="top" align="left" colspan="1">National mortality and 5-year relative survival data</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on deaths and survival</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Trends in incidence, mortality and survival are relatively stable over time</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Five-year survival proportion a reasonable proxy for clinical cure</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">6</td><td rowspan="2" valign="top" align="left" colspan="1">Rates from one regional registry within the country</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/population size</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Incidence rates in single region representative nationally</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">7</td><td rowspan="2" valign="top" align="left" colspan="1">Rates from multiple regional registries within the country</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/population size</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Incidence rates in combined regions representative nationally</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">8</td><td rowspan="2" valign="top" align="left" colspan="1">Data from all sites by age and sex and frequency data by cancer site</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on total cancer cases</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Total cases and cancer-specific frequencies representative nationally</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">9</td><td rowspan="2" valign="top" align="left" colspan="1">Data from neighbouring countries</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013; Availability of robust data on cases/population size</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02013; Incidence rates in combined neighbouring countries representative nationally</td></tr></tbody></table><table-wrap-foot><p>M:I: mortality:incidence.</p></table-wrap-foot></table-wrap><p>All analyses were performed using the R software package (The R Project for Statistical Computing, Vienna, Austria).</p><sec><title>Method 1</title><p>Method&#x000a0;1 is based on projections of incidence rates. We performed two projections: (i)&#x000a0;for 1A we used the computer program NORDPRED<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> and applied long-term data (1983&#x02013;2007) and; (ii)&#x000a0;for 1B we used the computer program DEPPRED<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> and applied medium-term data (1998&#x02013;2007).</p></sec><sec><title>Methods 2 to 7</title><p>For methods&#x000a0;2 to 7, we used incidence and/or mortality data from 2003&#x02013;2007 to simulate a real-life situation where data from the latest volume of <italic>Cancer incidence in five continents (Vol. X)</italic> would be used.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> The 2010 Norwegian mortality data used in methods&#x000a0;3 to 5 were estimated as in GLOBOCAN 2012 by projecting rates for the period 1988&#x02013;2007 to 2008&#x02013;2012.</p><p>In method&#x000a0;3, mortality:incidence (M:I) ratios from regional registries are used as a proxy for national case-fatality rates. National incidence rates can then be inferred from national mortality data along with the M:I ratio. This is useful where regional registries are numerous but not necessarily nationally representative, as in Italy<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> or Japan.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Where no such regional population-based data are available, data from neighbouring countries can be used (method&#x000a0;4). To generate the M:I ratios used in method&#x000a0;3, we included recorded cancer cases and deaths from all regions of Norway except for the south-eastern region (that includes Oslo). In some high-income countries (e.g. France or Japan) national estimates are derived from regional cancer registry data that do not cover the capital city which is usually highly populated. We also included recorded cases and deaths from other Nordic countries for cancer sites with less than a hundred deaths in Norway (e.g. cancers of the larynx, testis and thyroid and Hodgkin lymphoma).</p><p>Method&#x000a0;5 estimates national cancer incidence by using national mortality and 5-year relative cancer survival data, using the equation:<disp-formula id="E1"><italic>M</italic>&#x02009;=&#x02009;<italic>I</italic>(1&#x02013;<italic>S</italic>)<label>(1)</label></disp-formula>where <italic>M</italic> is the mortality rate, <italic>I</italic> is incidence rate and <italic>S</italic> is the 5-year relative survival proportion.</p><p>Method&#x000a0;6 was based on incidence data from the northern and western regions of Norway, while we selected the south-eastern region (including Oslo) for method&#x000a0;7. For GLOBOCAN estimations, regional incidence data are often only available from large cities, particularly in low- and middle-income countries (e.g. Uganda, Zimbabwe).</p></sec><sec><title>Methods&#x000a0;8 and 9</title><p>The incidence rates from neighbouring countries used in methods&#x000a0;8 and 9 were computed using data from Nordic countries for the period 2009&#x02013;2011.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>In 2010, 14&#x02009;507 new cancer cases were recorded in Norwegian men and 12&#x02009;466 in women. Our corresponding estimates, based on GLOBOCAN methods, differed by 5.7&#x02013;18.8% (834 to 2341 cases) from the observed data (excluding method 5). <xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref> summarizes the sex-specific numerical differences according to each method, with under- and overestimates reported separately, as well as the overall difference as a percentage with observed data.</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig.&#x000a0;3</label><caption><p>Observed and estimated cancer incidence in Norway, 2010</p></caption><p>Note: Observed data obtained from the Norwegian Cancer Registry in 2010. Estimates are based on the nine methods used in GLOBOCAN 2012.</p><graphic xlink:href="BLT.15.164384-F3"/></fig><p>Comparing incidence estimates to observed data across cancer sites by sex, estimates based on data from one regional cancer registry (method&#x000a0;7) performed best in men (mean of 5.7%, or 834 difference between estimated and observed cases), while projection of medium-term historical rates (method&#x000a0;1B) performed best in women (mean: 6.1% difference; 763 cases). When considering both sexes together, and among the methods usually used in high-income countries (methods&#x000a0;1 to 4), the most recent recorded rates applied to 2010 population (method&#x000a0;2) performed well with a 6.4% (1726 cases) difference between observed and estimated cases. However, when prostate and breast cancers were excluded, projection of rates (methods&#x000a0;1A and 1B) produced very similar overall estimates to those from method&#x000a0;2 (at most a 5.0% (723 cases, 1B) and 7.7% (958 cases, 1A) difference; <xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>). Apart from methods 1A, 1B and 5, all methods tended to underestimate the total number of cases.</p><p>Our estimates by cancer sites show variability in the performance of the different methods (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>). Overall, methods commonly used in high-income countries performed quite well in estimating recent cancer incidence in Norway. Method&#x000a0;1A produced the closest estimates to observed data for lung cancer in both men and women (&#x02212;0.5%; &#x02212;7 cases and &#x02212;1.1%; &#x02212;13 cases, respectively). It also performed well for colorectal cancer in men (&#x02212;0.1%; &#x02212;1 case) and women (+2.4%; +45 cases). On the other hand, prostate cancer cases were overestimated by this method (+19.4%; +881 cases). Method&#x000a0;2 performed better than method&#x000a0;1A for breast (+2.3%; +67 cases) and prostate (&#x02212;5.1%; &#x02212;231 cases; <xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>) cancers. Method&#x000a0;2 estimates for lung cancer were satisfactory in men (+1.2%; +18 cases) but less so in women (&#x02212;13.9%; &#x02212;168 cases; <xref ref-type="fig" rid="F6">Fig.&#x000a0;6</xref>). Methods 3 and 4 generally produced underestimations at major cancer sites except for melanoma of skin in women (+17.4%; +139 cases and +34.0%; +271 cases using methods 3 and 4, respectively). These two methods performed less well for rare cancers (e.g. gallbladder cancer or Hodgkin lymphoma) or those with a good prognosis (e.g. testis or thyroid cancers; <xref ref-type="table" rid="T2">Table&#x000a0;2</xref> and <xref ref-type="table" rid="T3">Table&#x000a0;3</xref>).</p><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig.&#x000a0;4</label><caption><p>Observed and estimated cancer incidence for the five most common cancers in Norway, 2010</p></caption><p>Notes: Observed data obtained from the Norwegian Cancer Registry in 2010. Estimates are based on the nine methods used in GLOBOCAN 2012.</p><graphic xlink:href="BLT.15.164384-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig.&#x000a0;5</label><caption><p>Observed and estimated incidence of prostate cancer (C61), Norway, 1999&#x02013;2010</p></caption><p>Notes: Observed data obtained from the Norwegian Cancer Registry in 2010. Estimates are based on methods&#x000a0;1A and 2 used in GLOBOCAN 2012.</p><graphic xlink:href="BLT.15.164384-F5"/></fig><fig id="F6" fig-type="figure" orientation="portrait" position="float"><label>Fig.&#x000a0;6</label><caption><p>Observed and estimated incidence of lung cancer (C33&#x02013;34) in females, Norway, 1999&#x02013;2010</p></caption><p>Notes: Observed data obtained from the Norwegian Cancer Registry in 2010. Estimates are based on methods&#x000a0;1A and 2 used in GLOBOCAN 2012.</p><graphic xlink:href="BLT.15.164384-F6"/></fig><table-wrap id="T2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><title>Cancer incidence in males (Norwegian Cancer Registry, 2010) and estimates using GLOBOCAN methods</title></caption><table frame="hsides" rules="groups"><col width="163" span="1"/><col width="70" span="1"/><col width="70" span="1"/><col width="79" span="1"/><col width="73" span="1"/><col width="78" span="1"/><col width="85" span="1"/><col width="78" span="1"/><col width="77" span="1"/><col width="77" span="1"/><col width="85" span="1"/><col width="85" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Site (ICD-10 code)</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">No. of observed cases</th><th colspan="10" valign="top" align="center" scope="colgroup" rowspan="1">No. of estimated cases (% difference from observed cases)<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Method 1A</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 1B</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 2</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 3</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 4</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 5</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 6</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 7</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 8</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 9</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Head and neck (C00&#x02013;14)</td><td valign="top" align="center" rowspan="1" colspan="1">324</td><td valign="top" align="center" rowspan="1" colspan="1">279 (&#x02212;13.9)</td><td valign="top" align="center" rowspan="1" colspan="1">288 (&#x02212;11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">287 (&#x02212;11.4)</td><td valign="top" align="center" rowspan="1" colspan="1">306 (&#x02212;5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">246 (&#x02212;24.1)</td><td valign="top" align="center" rowspan="1" colspan="1">221 (&#x02212;31.8)</td><td valign="top" align="center" rowspan="1" colspan="1">292 (&#x02212;9.9)</td><td valign="top" align="center" rowspan="1" colspan="1">298 (&#x02212;8.0)</td><td valign="top" align="center" rowspan="1" colspan="1">291 (&#x02212;10.2)</td><td valign="top" align="center" rowspan="1" colspan="1">335 (3.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Oesophagus (C15)</td><td valign="top" align="center" rowspan="1" colspan="1">168</td><td valign="top" align="center" rowspan="1" colspan="1">159 (&#x02212;5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">160 (&#x02212;4.8)</td><td valign="top" align="center" rowspan="1" colspan="1">154 (&#x02212;8.3)</td><td valign="top" align="center" rowspan="1" colspan="1">181 (7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">170 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">182 (8.3)</td><td valign="top" align="center" rowspan="1" colspan="1">146 (&#x02212;13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">166 (&#x02212;1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">155 (&#x02212;7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">217 (29.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Stomach (C16)</td><td valign="top" align="center" rowspan="1" colspan="1">293</td><td valign="top" align="center" rowspan="1" colspan="1">296 (1.0)</td><td valign="top" align="center" rowspan="1" colspan="1">294 (0.3)</td><td valign="top" align="center" rowspan="1" colspan="1">355 (21.2)</td><td valign="top" align="center" rowspan="1" colspan="1">281 (&#x02212;4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">269 (&#x02212;8.2)</td><td valign="top" align="center" rowspan="1" colspan="1">276 (&#x02212;5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">431 (47.1)</td><td valign="top" align="center" rowspan="1" colspan="1">296 (1.0)</td><td valign="top" align="center" rowspan="1" colspan="1">238 (&#x02212;18.8)</td><td valign="top" align="center" rowspan="1" colspan="1">297 (1.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Colon-rectum (C18&#x02013;21)</td><td valign="top" align="center" rowspan="1" colspan="1">1948</td><td valign="top" align="center" rowspan="1" colspan="1">1947 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1882 (&#x02212;3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1895 (&#x02212;2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">1834 (&#x02212;5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1668 (&#x02212;14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1994 (2.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2083 (6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1797 (&#x02212;7.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1617 (&#x02212;17.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1428 (&#x02212;26.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Liver (C22)</td><td valign="top" align="center" rowspan="1" colspan="1">120</td><td valign="top" align="center" rowspan="1" colspan="1">105 (&#x02212;12.5)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (&#x02212;18.3)</td><td valign="top" align="center" rowspan="1" colspan="1">94 (&#x02212;21.7)</td><td valign="top" align="center" rowspan="1" colspan="1">100 (&#x02212;16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">99 (&#x02212;17.5)</td><td valign="top" align="center" rowspan="1" colspan="1">112 (&#x02212;6.7)</td><td valign="top" align="center" rowspan="1" colspan="1">91 (&#x02212;24.2)</td><td valign="top" align="center" rowspan="1" colspan="1">94 (&#x02212;21.7)</td><td valign="top" align="center" rowspan="1" colspan="1">113 (&#x02212;5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">193 (60.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gallbladder (C23&#x02013;24)</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">76 (4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (&#x02212;12.3)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (&#x02212;8.2)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (&#x02212;41.1)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (&#x02212;65.8)</td><td valign="top" align="center" rowspan="1" colspan="1">28 (&#x02212;61.6)</td><td valign="top" align="center" rowspan="1" colspan="1">68 (&#x02212;6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (&#x02212;2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">60 (&#x02212;17.8)</td><td valign="top" align="center" rowspan="1" colspan="1">89 (21.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pancreas (C25)</td><td valign="top" align="center" rowspan="1" colspan="1">332</td><td valign="top" align="center" rowspan="1" colspan="1">377 (13.6)</td><td valign="top" align="center" rowspan="1" colspan="1">385 (16.0)</td><td valign="top" align="center" rowspan="1" colspan="1">352 (6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">376 (13.3)</td><td valign="top" align="center" rowspan="1" colspan="1">309 (&#x02212;6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">367 (10.5)</td><td valign="top" align="center" rowspan="1" colspan="1">343 (3.3)</td><td valign="top" align="center" rowspan="1" colspan="1">355 (6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">281 (&#x02212;15.4)</td><td valign="top" align="center" rowspan="1" colspan="1">329 (&#x02212;0.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Larynx (C32)</td><td valign="top" align="center" rowspan="1" colspan="1">97</td><td valign="top" align="center" rowspan="1" colspan="1">89 (&#x02212;8.3)</td><td valign="top" align="center" rowspan="1" colspan="1">82 (&#x02212;15.5)</td><td valign="top" align="center" rowspan="1" colspan="1">107 (10.3)</td><td valign="top" align="center" rowspan="1" colspan="1">113 (16.5)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">112 (15.5)</td><td valign="top" align="center" rowspan="1" colspan="1">119 (22.7)</td><td valign="top" align="center" rowspan="1" colspan="1">110 (13.4)</td><td valign="top" align="center" rowspan="1" colspan="1">113 (16.5)</td><td valign="top" align="center" rowspan="1" colspan="1">83 (&#x02212;14.4)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (7.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lung (C33&#x02013;34)</td><td valign="top" align="center" rowspan="1" colspan="1">1561</td><td valign="top" align="center" rowspan="1" colspan="1">1554 (&#x02212;0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1617 (3.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1579 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">1494 (&#x02212;4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1338 (&#x02212;14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1439 (&#x02212;7.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1654 (6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1549 (&#x02212;0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1357 (&#x02212;13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1357 (&#x02212;13.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Melanoma of skin (C43)</td><td valign="top" align="center" rowspan="1" colspan="1">773</td><td valign="top" align="center" rowspan="1" colspan="1">616 (&#x02212;20.3)</td><td valign="top" align="center" rowspan="1" colspan="1">672 (&#x02212;13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">592 (&#x02212;23.4)</td><td valign="top" align="center" rowspan="1" colspan="1">669 (&#x02212;13.5)</td><td valign="top" align="center" rowspan="1" colspan="1">726 (&#x02212;6.1)</td><td valign="top" align="center" rowspan="1" colspan="1">815 (5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">503 (&#x02212;34.9)</td><td valign="top" align="center" rowspan="1" colspan="1">646 (&#x02212;16.4)</td><td valign="top" align="center" rowspan="1" colspan="1">741 (&#x02212;4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">578 (&#x02212;25.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prostate (C61)</td><td valign="top" align="center" rowspan="1" colspan="1">4533</td><td valign="top" align="center" rowspan="1" colspan="1">5414 (19.4)</td><td valign="top" align="center" rowspan="1" colspan="1">5487 (21.1)</td><td valign="top" align="center" rowspan="1" colspan="1">4302 (&#x02212;5.1)</td><td valign="top" align="center" rowspan="1" colspan="1">4165 (&#x02212;8.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3897 (&#x02212;14.0)</td><td valign="top" align="center" rowspan="1" colspan="1">8741 (92.8)</td><td valign="top" align="center" rowspan="1" colspan="1">4397 (&#x02212;3.0)</td><td valign="top" align="center" rowspan="1" colspan="1">4286 (&#x02212;5.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3805 (&#x02212;16.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3815 (&#x02212;15.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Testis (C62)</td><td valign="top" align="center" rowspan="1" colspan="1">288</td><td valign="top" align="center" rowspan="1" colspan="1">299 (3.8)</td><td valign="top" align="center" rowspan="1" colspan="1">303 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">272 (&#x02212;5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">229 (&#x02212;20.5)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">230 (&#x02212;20.1)</td><td valign="top" align="center" rowspan="1" colspan="1">172 (&#x02212;40.3)</td><td valign="top" align="center" rowspan="1" colspan="1">282 (&#x02212;2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">256 (&#x02212;11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">232 (&#x02212;19.4)</td><td valign="top" align="center" rowspan="1" colspan="1">185 (&#x02212;35.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kidney (C64&#x02013;66)</td><td valign="top" align="center" rowspan="1" colspan="1">484</td><td valign="top" align="center" rowspan="1" colspan="1">463 (&#x02212;4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">452 (&#x02212;6.6)</td><td valign="top" align="center" rowspan="1" colspan="1">407 (&#x02212;15.9)</td><td valign="top" align="center" rowspan="1" colspan="1">404 (&#x02212;16.5)</td><td valign="top" align="center" rowspan="1" colspan="1">296 (&#x02212;38.8)</td><td valign="top" align="center" rowspan="1" colspan="1">418 (&#x02212;13.6)</td><td valign="top" align="center" rowspan="1" colspan="1">405 (&#x02212;16.3)</td><td valign="top" align="center" rowspan="1" colspan="1">406 (&#x02212;16.1)</td><td valign="top" align="center" rowspan="1" colspan="1">428 (&#x02212;11.6)</td><td valign="top" align="center" rowspan="1" colspan="1">400 (&#x02212;17.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bladder (C67)</td><td valign="top" align="center" rowspan="1" colspan="1">938</td><td valign="top" align="center" rowspan="1" colspan="1">1045 (11.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1050 (11.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1000 (6.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1071 (14.2)</td><td valign="top" align="center" rowspan="1" colspan="1">843 (&#x02212;10.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1078 (14.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1060 (13.0)</td><td valign="top" align="center" rowspan="1" colspan="1">956 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1">809 (&#x02212;13.8)</td><td valign="top" align="center" rowspan="1" colspan="1">924 (&#x02212;1.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brain (C70&#x02013;72)</td><td valign="top" align="center" rowspan="1" colspan="1">518</td><td valign="top" align="center" rowspan="1" colspan="1">628 (21.2)</td><td valign="top" align="center" rowspan="1" colspan="1">625 (20.7)</td><td valign="top" align="center" rowspan="1" colspan="1">530 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">562 (8.5)</td><td valign="top" align="center" rowspan="1" colspan="1">368 (&#x02212;29.0)</td><td valign="top" align="center" rowspan="1" colspan="1">563 (8.7)</td><td valign="top" align="center" rowspan="1" colspan="1">527 (1.7)</td><td valign="top" align="center" rowspan="1" colspan="1">515 (&#x02212;0.6)</td><td valign="top" align="center" rowspan="1" colspan="1">452 (&#x02212;12.7)</td><td valign="top" align="center" rowspan="1" colspan="1">412 (&#x02212;20.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Thyroid (C73)</td><td valign="top" align="center" rowspan="1" colspan="1">77</td><td valign="top" align="center" rowspan="1" colspan="1">80 (3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">87 (13.0)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (&#x02212;13.0)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (&#x02212;50.7)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">38 (&#x02212;50.7)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (&#x02212;9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">61 (&#x02212;20.8)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (&#x02212;7.8)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (&#x02212;15.6)</td><td valign="top" align="center" rowspan="1" colspan="1">87 (13.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hodgkin lymphoma (C81)</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">94 (28.8)</td><td valign="top" align="center" rowspan="1" colspan="1">73 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">76 (4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x02212;26.0)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">47 (&#x02212;35.6)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (&#x02212;38.4)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (&#x02212;13.7)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (9.6)</td><td valign="top" align="center" rowspan="1" colspan="1">62 (&#x02212;15.1)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (&#x02212;13.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-Hodgkin lymphoma (C82&#x02013;85, C96)</td><td valign="top" align="center" rowspan="1" colspan="1">499</td><td valign="top" align="center" rowspan="1" colspan="1">483 (&#x02212;3.2)</td><td valign="top" align="center" rowspan="1" colspan="1">485 (&#x02212;2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">451 (&#x02212;9.6)</td><td valign="top" align="center" rowspan="1" colspan="1">426 (&#x02212;14.6)</td><td valign="top" align="center" rowspan="1" colspan="1">391 (&#x02212;21.6)</td><td valign="top" align="center" rowspan="1" colspan="1">444 (&#x02212;11.0)</td><td valign="top" align="center" rowspan="1" colspan="1">420 (&#x02212;15.8)</td><td valign="top" align="center" rowspan="1" colspan="1">473 (&#x02212;5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">441 (&#x02212;11.6)</td><td valign="top" align="center" rowspan="1" colspan="1">455 (&#x02212;8.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Multiple myeloma (C88, C90)</td><td valign="top" align="center" rowspan="1" colspan="1">218</td><td valign="top" align="center" rowspan="1" colspan="1">210 (&#x02212;3.7)</td><td valign="top" align="center" rowspan="1" colspan="1">211 (&#x02212;3.2)</td><td valign="top" align="center" rowspan="1" colspan="1">202 (&#x02212;7.3)</td><td valign="top" align="center" rowspan="1" colspan="1">186 (&#x02212;14.7)</td><td valign="top" align="center" rowspan="1" colspan="1">169 (&#x02212;22.5)</td><td valign="top" align="center" rowspan="1" colspan="1">216 (&#x02212;0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">187 (&#x02212;14.2)</td><td valign="top" align="center" rowspan="1" colspan="1">209 (&#x02212;4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">194 (&#x02212;11.0)</td><td valign="top" align="center" rowspan="1" colspan="1">162 (&#x02212;25.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Leukaemia (C91&#x02013;95)</td><td valign="top" align="center" rowspan="1" colspan="1">363</td><td valign="top" align="center" rowspan="1" colspan="1">339 (&#x02212;6.6)</td><td valign="top" align="center" rowspan="1" colspan="1">344 (&#x02212;5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">336 (&#x02212;7.4)</td><td valign="top" align="center" rowspan="1" colspan="1">310 (&#x02212;14.6)</td><td valign="top" align="center" rowspan="1" colspan="1">292 (&#x02212;19.6)</td><td valign="top" align="center" rowspan="1" colspan="1">403 (11.0)</td><td valign="top" align="center" rowspan="1" colspan="1">290 (&#x02212;20.1)</td><td valign="top" align="center" rowspan="1" colspan="1">361 (&#x02212;0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">368 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">313 (&#x02212;13.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other and unspecified</td><td valign="top" align="center" rowspan="1" colspan="1">827</td><td valign="top" align="center" rowspan="1" colspan="1">858 (3.8)</td><td valign="top" align="center" rowspan="1" colspan="1">867 (4.8)</td><td valign="top" align="center" rowspan="1" colspan="1">829 (0.2)</td><td valign="top" align="center" rowspan="1" colspan="1">662 (&#x02212;20.0)</td><td valign="top" align="center" rowspan="1" colspan="1">569 (&#x02212;31.2)</td><td valign="top" align="center" rowspan="1" colspan="1">759 (&#x02212;8.2)</td><td valign="top" align="center" rowspan="1" colspan="1">826 (&#x02212;0.1)</td><td valign="top" align="center" rowspan="1" colspan="1">845 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">752 (&#x02212;9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">839 (1.5)</td></tr></tbody></table><table-wrap-foot><p>ICD-10: International statistical classification of diseases and related health problems, 10th revision; M:I mortality:incidence.</p><p><sup>a</sup> Cases/deaths from neighbouring countries were added to compute M:I ratios.</p></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Cancer incidence in females (Norwegian Cancer Registry, 2010) and estimates using GLOBOCAN methods</title></caption><table frame="hsides" rules="groups"><col width="175" span="1"/><col width="70" span="1"/><col width="70" span="1"/><col width="70" span="1"/><col width="77" span="1"/><col width="78" span="1"/><col width="85" span="1"/><col width="76" span="1"/><col width="77" span="1"/><col width="78" span="1"/><col width="85" span="1"/><col width="85" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Site (ICD-10 code)</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">No. of observed cases</th><th colspan="10" valign="top" align="center" scope="colgroup" rowspan="1">No. of estimated cases (% difference from observed cases)<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Method 1A</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 1B</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 2</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 3</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 4</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 5</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 6</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 7</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 8</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Method 9</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Head and neck (C00&#x02013;14)</td><td valign="top" align="center" rowspan="1" colspan="1">188</td><td valign="top" align="center" rowspan="1" colspan="1">174 (&#x02212;7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">187 (&#x02212;0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">163 (&#x02212;3.3)</td><td valign="top" align="center" rowspan="1" colspan="1">165 (&#x02212;12.2)</td><td valign="top" align="center" rowspan="1" colspan="1">136 (&#x02212;27.7)</td><td valign="top" align="center" rowspan="1" colspan="1">157 (&#x02212;16.5)</td><td valign="top" align="center" rowspan="1" colspan="1">155 (&#x02212;17.6)</td><td valign="top" align="center" rowspan="1" colspan="1">174 (&#x02212;7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">192 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">185 (&#x02212;1.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Oesophagus (C15)</td><td valign="top" align="center" rowspan="1" colspan="1">58</td><td valign="top" align="center" rowspan="1" colspan="1">62 (6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (&#x02212;3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (&#x02212;3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (&#x02212;3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (&#x02212;3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">61 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">53 (&#x02212;8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (10.3)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x02212;6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (46.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Stomach (C16)</td><td valign="top" align="center" rowspan="1" colspan="1">196</td><td valign="top" align="center" rowspan="1" colspan="1">201 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">218 (11.2)</td><td valign="top" align="center" rowspan="1" colspan="1">230 (17.4)</td><td valign="top" align="center" rowspan="1" colspan="1">210 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">188 (&#x02212;4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">209 (6.6)</td><td valign="top" align="center" rowspan="1" colspan="1">280 (42.9)</td><td valign="top" align="center" rowspan="1" colspan="1">200 (2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (&#x02212;23.0)</td><td valign="top" align="center" rowspan="1" colspan="1">197 (0.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Colon-rectum (C18&#x02013;21)</td><td valign="top" align="center" rowspan="1" colspan="1">1894</td><td valign="top" align="center" rowspan="1" colspan="1">1939 (2.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1947 (2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1856 (&#x02212;2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1732 (&#x02212;8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1647 (&#x02212;13.0)</td><td valign="top" align="center" rowspan="1" colspan="1">2217 (17.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1961 (3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1781 (&#x02212;6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1671 (&#x02212;11.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1309 (&#x02212;30.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Liver (C22)</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">49 (&#x02212;32.9)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (&#x02212;19.2)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (&#x02212;32.9)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (&#x02212;11.0)</td><td valign="top" align="center" rowspan="1" colspan="1">86 (17.8)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x02212;26.0)</td><td valign="top" align="center" rowspan="1" colspan="1">48 (&#x02212;34.3)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (&#x02212;13.7)</td><td valign="top" align="center" rowspan="1" colspan="1">94 (28.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gallbladder (C23&#x02013;24)</td><td valign="top" align="center" rowspan="1" colspan="1">84</td><td valign="top" align="center" rowspan="1" colspan="1">83 (&#x02212;1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">80 (&#x02212;4.8)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (&#x02212;47.6)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (&#x02212;72.6)</td><td valign="top" align="center" rowspan="1" colspan="1">34 (&#x02212;59.5)</td><td valign="top" align="center" rowspan="1" colspan="1">72 (&#x02212;14.3)</td><td valign="top" align="center" rowspan="1" colspan="1">79 (&#x02212;6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">75 (&#x02212;10.7)</td><td valign="top" align="center" rowspan="1" colspan="1">96 (14.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pancreas (C25)</td><td valign="top" align="center" rowspan="1" colspan="1">358</td><td valign="top" align="center" rowspan="1" colspan="1">363 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">369 (3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">355 (&#x02212;0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">361 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">286 (&#x02212;20.1)</td><td valign="top" align="center" rowspan="1" colspan="1">367 (2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">342 (&#x02212;4.5)</td><td valign="top" align="center" rowspan="1" colspan="1">348 (&#x02212;2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">303 (&#x02212;15.4)</td><td valign="top" align="center" rowspan="1" colspan="1">331 (&#x02212;7.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Larynx (C32)</td><td valign="top" align="center" rowspan="1" colspan="1">18</td><td valign="top" align="center" rowspan="1" colspan="1">10 (&#x02212;44.4)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (&#x02212;22.2)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (&#x02212;16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (&#x02212;5.6)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">18 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (&#x02212;22.2)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (16.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lung (C33&#x02013;34)</td><td valign="top" align="center" rowspan="1" colspan="1">1210</td><td valign="top" align="center" rowspan="1" colspan="1">1197 (&#x02212;1.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1328 (9.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1042 (&#x02212;13.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1172 (&#x02212;3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1026 (&#x02212;15.2)</td><td valign="top" align="center" rowspan="1" colspan="1">1118 (&#x02212;7.6)</td><td valign="top" align="center" rowspan="1" colspan="1">965 (&#x02212;20.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1095 (&#x02212;9.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1173 (&#x02212;3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1171 (&#x02212;3.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Melanoma of skin (C43)</td><td valign="top" align="center" rowspan="1" colspan="1">797</td><td valign="top" align="center" rowspan="1" colspan="1">698 (&#x02212;12.4)</td><td valign="top" align="center" rowspan="1" colspan="1">707 (&#x02212;11.3)</td><td valign="top" align="center" rowspan="1" colspan="1">630 (&#x02212;21.0)</td><td valign="top" align="center" rowspan="1" colspan="1">936 (17.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1068 (34.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1591 (99.6)</td><td valign="top" align="center" rowspan="1" colspan="1">557 (&#x02212;30.1)</td><td valign="top" align="center" rowspan="1" colspan="1">675 (&#x02212;15.3)</td><td valign="top" align="center" rowspan="1" colspan="1">793 (&#x02212;0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">646 (&#x02212;19.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Breast (C50)</td><td valign="top" align="center" rowspan="1" colspan="1">2891</td><td valign="top" align="center" rowspan="1" colspan="1">3059 (5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">2896 (0.2)</td><td valign="top" align="center" rowspan="1" colspan="1">2958 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">2672 (&#x02212;7.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2550 (&#x02212;11.8)</td><td valign="top" align="center" rowspan="1" colspan="1">4540 (57.0)</td><td valign="top" align="center" rowspan="1" colspan="1">2818 (&#x02212;2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3062 (5.9)</td><td valign="top" align="center" rowspan="1" colspan="1">2772 (&#x02212;4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3651 (26.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cervix (C53)</td><td valign="top" align="center" rowspan="1" colspan="1">307</td><td valign="top" align="center" rowspan="1" colspan="1">285 (&#x02212;7.2)</td><td valign="top" align="center" rowspan="1" colspan="1">296 (&#x02212;3.6)</td><td valign="top" align="center" rowspan="1" colspan="1">310 (1.0)</td><td valign="top" align="center" rowspan="1" colspan="1">282 (&#x02212;8.1)</td><td valign="top" align="center" rowspan="1" colspan="1">234 (&#x02212;23.8)</td><td valign="top" align="center" rowspan="1" colspan="1">338 (10.1)</td><td valign="top" align="center" rowspan="1" colspan="1">330 (7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">312 (1.6)</td><td valign="top" align="center" rowspan="1" colspan="1">286 (&#x02212;6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">250 (&#x02212;18.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Corpus uteri (C54)</td><td valign="top" align="center" rowspan="1" colspan="1">744</td><td valign="top" align="center" rowspan="1" colspan="1">801 (7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">763 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">715 (&#x02212;3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">639 (&#x02212;14.1)</td><td valign="top" align="center" rowspan="1" colspan="1">632 (&#x02212;15.1)</td><td valign="top" align="center" rowspan="1" colspan="1">691 (&#x02212;7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">721 (&#x02212;3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">740 (&#x02212;0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">721 (&#x02212;3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">599 (&#x02212;19.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ovary (C56)</td><td valign="top" align="center" rowspan="1" colspan="1">479</td><td valign="top" align="center" rowspan="1" colspan="1">432 (&#x02212;9.8)</td><td valign="top" align="center" rowspan="1" colspan="1">462 (&#x02212;3.6)</td><td valign="top" align="center" rowspan="1" colspan="1">489 (2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">451 (&#x02212;5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">445 (&#x02212;7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">559 (16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">477 (&#x02212;0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">509 (6.3)</td><td valign="top" align="center" rowspan="1" colspan="1">457 (&#x02212;4.6)</td><td valign="top" align="center" rowspan="1" colspan="1">392 (&#x02212;18.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kidney (C64&#x02013;66)</td><td valign="top" align="center" rowspan="1" colspan="1">246</td><td valign="top" align="center" rowspan="1" colspan="1">269 (9.3)</td><td valign="top" align="center" rowspan="1" colspan="1">272 (10.6)</td><td valign="top" align="center" rowspan="1" colspan="1">237 (&#x02212;3.7)</td><td valign="top" align="center" rowspan="1" colspan="1">215 (&#x02212;12.6)</td><td valign="top" align="center" rowspan="1" colspan="1">140 (&#x02212;43.1)</td><td valign="top" align="center" rowspan="1" colspan="1">263 (6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">232 (&#x02212;5.7)</td><td valign="top" align="center" rowspan="1" colspan="1">229 (&#x02212;6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">216 (&#x02212;12.2)</td><td valign="top" align="center" rowspan="1" colspan="1">243 (&#x02212;1.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bladder (C67)</td><td valign="top" align="center" rowspan="1" colspan="1">359</td><td valign="top" align="center" rowspan="1" colspan="1">378 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">326 (&#x02212;9.2)</td><td valign="top" align="center" rowspan="1" colspan="1">349 (&#x02212;2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">351 (&#x02212;2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">321 (&#x02212;10.6)</td><td valign="top" align="center" rowspan="1" colspan="1">438 (22.0)</td><td valign="top" align="center" rowspan="1" colspan="1">353 (&#x02212;1.7)</td><td valign="top" align="center" rowspan="1" colspan="1">347 (&#x02212;3.3)</td><td valign="top" align="center" rowspan="1" colspan="1">329 (&#x02212;8.4)</td><td valign="top" align="center" rowspan="1" colspan="1">306 (&#x02212;14.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brain (C70&#x02013;72)</td><td valign="top" align="center" rowspan="1" colspan="1">629</td><td valign="top" align="center" rowspan="1" colspan="1">903 (43.6)</td><td valign="top" align="center" rowspan="1" colspan="1">858 (36.4)</td><td valign="top" align="center" rowspan="1" colspan="1">688 (9.4)</td><td valign="top" align="center" rowspan="1" colspan="1">663 (5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">407 (&#x02212;35.3)</td><td valign="top" align="center" rowspan="1" colspan="1">788 (25.3)</td><td valign="top" align="center" rowspan="1" colspan="1">672 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">672 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">542 (&#x02212;13.8)</td><td valign="top" align="center" rowspan="1" colspan="1">459 (&#x02212;27.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Thyroid (C73)</td><td valign="top" align="center" rowspan="1" colspan="1">206</td><td valign="top" align="center" rowspan="1" colspan="1">184 (&#x02212;10.7)</td><td valign="top" align="center" rowspan="1" colspan="1">176 (&#x02212;14.6)</td><td valign="top" align="center" rowspan="1" colspan="1">163 (&#x02212;20.9)</td><td valign="top" align="center" rowspan="1" colspan="1">189 (&#x02212;8.3)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">181 (&#x02212;12.1)</td><td valign="top" align="center" rowspan="1" colspan="1">236 (14.6)</td><td valign="top" align="center" rowspan="1" colspan="1">177 (&#x02212;14.1)</td><td valign="top" align="center" rowspan="1" colspan="1">152 (&#x02212;26.2)</td><td valign="top" align="center" rowspan="1" colspan="1">206 (0.0)</td><td valign="top" align="center" rowspan="1" colspan="1">242 (17.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hodgkin lymphoma (C81)</td><td valign="top" align="center" rowspan="1" colspan="1">57</td><td valign="top" align="center" rowspan="1" colspan="1">56 (&#x02212;1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x02212;5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (&#x02212;10.5)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (&#x02212;56.1)<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">23 (&#x02212;59.7)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (&#x02212;31.6)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (&#x02212;1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (&#x02212;12.3)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x02212;5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (&#x02212;5.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-Hodgkin lymphoma (C82&#x02013;85, C96)</td><td valign="top" align="center" rowspan="1" colspan="1">412</td><td valign="top" align="center" rowspan="1" colspan="1">398 (&#x02212;3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">390 (&#x02212;5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">374 (&#x02212;9.2)</td><td valign="top" align="center" rowspan="1" colspan="1">292 (&#x02212;29.1)</td><td valign="top" align="center" rowspan="1" colspan="1">274 (&#x02212;33.5)</td><td valign="top" align="center" rowspan="1" colspan="1">436 (5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">371 (&#x02212;10.0)</td><td valign="top" align="center" rowspan="1" colspan="1">369 (&#x02212;10.4)</td><td valign="top" align="center" rowspan="1" colspan="1">381 (&#x02212;7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">385 (&#x02212;6.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Multiple myeloma (C88, C90)</td><td valign="top" align="center" rowspan="1" colspan="1">159</td><td valign="top" align="center" rowspan="1" colspan="1">164 (3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">164 (3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">162 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1">126 (&#x02212;20.8)</td><td valign="top" align="center" rowspan="1" colspan="1">130 (&#x02212;18.2)</td><td valign="top" align="center" rowspan="1" colspan="1">207 (30.2)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (&#x02212;5.0)</td><td valign="top" align="center" rowspan="1" colspan="1">171 (7.6)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (&#x02212;5.0)</td><td valign="top" align="center" rowspan="1" colspan="1">129 (&#x02212;18.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Leukaemia (C91&#x02013;95)</td><td valign="top" align="center" rowspan="1" colspan="1">272</td><td valign="top" align="center" rowspan="1" colspan="1">260 (&#x02212;4.4)</td><td valign="top" align="center" rowspan="1" colspan="1">253 (&#x02212;7.0)</td><td valign="top" align="center" rowspan="1" colspan="1">248 (&#x02212;8.8)</td><td valign="top" align="center" rowspan="1" colspan="1">216 (&#x02212;20.6)</td><td valign="top" align="center" rowspan="1" colspan="1">197 (&#x02212;27.6)</td><td valign="top" align="center" rowspan="1" colspan="1">307 (12.9)</td><td valign="top" align="center" rowspan="1" colspan="1">223 (&#x02212;18.0)</td><td valign="top" align="center" rowspan="1" colspan="1">265 (&#x02212;2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">276 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">218 (&#x02212;19.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other and unspecified</td><td valign="top" align="center" rowspan="1" colspan="1">829</td><td valign="top" align="center" rowspan="1" colspan="1">910 (9.8)</td><td valign="top" align="center" rowspan="1" colspan="1">857 (3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">855 (3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">762 (&#x02212;8.1)</td><td valign="top" align="center" rowspan="1" colspan="1">726 (&#x02212;12.4)</td><td valign="top" align="center" rowspan="1" colspan="1">921 (11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">807 (&#x02212;2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">886 (6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">767 (&#x02212;7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">876 (5.7)</td></tr></tbody></table><table-wrap-foot><p>ICD-10: International statistical classification of diseases and related health problems, 10th revision; M:I mortality:incidence.</p><p><sup>a</sup> Cases/deaths from neighbouring countries were added to compute M:I ratios.</p></table-wrap-foot></table-wrap><p>Among the methods commonly used in low- and middle-income countries (methods&#x000a0;5 to 9), the method using mortality combined with 5-year relative survival proportion (method&#x000a0;5) produced quite large overestimates for cancers associated with good survival including melanoma of skin in women (+99.6%; +794 cases), prostate (+92.8%; +4208 cases) and breast (+57.0%; +1649 cases) and underestimates for cancers with small numbers of deaths, including testicular (&#x02212;40.3%; &#x02212;116 cases) or gallbladder (&#x02212;61.6%; &#x02212;45 cases in men, &#x02212;59.5%; &#x02212;50 cases in women) cancers. Estimates for lung and pancreatic cancers were similar to, or more accurate than, those obtained from method 3 and 4 (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref> and <xref ref-type="table" rid="T3">Table&#x000a0;3</xref>).</p><p>The performance of methods using data from one or more regional registries (methods&#x000a0;6 and 7) varied greatly by cancer site. Estimates for prostate, colorectal, lung and breast cancers were reasonable (less than 8% difference between estimates and observed data); method 6, however, underestimated female lung cancer estimates in our study (&#x02212;20.3%; &#x02212;245 cases). Despite the use of observed data (instead of GLOBOCAN estimates), results from methods&#x000a0;8 and 9 were also almost exclusively underestimates and their accuracy varied greatly by cancer site and sex (<xref ref-type="table" rid="T2">Table&#x000a0;2</xref> and <xref ref-type="table" rid="T3">Table&#x000a0;3</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Our results, validated against the high-quality data available from the Norwegian Cancer Registry, confirm that projections of historical national data are among the best methods to predict recent cancer incidence. They also suggest that, in selected populations, a site-specific approach is warranted for cancers where the level of incidence is driven by changes in diagnosis patterns (e.g. thyroid) or screening (e.g. breast, prostate). They also illustrate how the accuracy of national estimates based on geographic proxies &#x02013; including data from regional registries or neighbouring countries &#x02013; is highly dependent on the extent to which these datasets are representative of the scale and profile of the country of interest.</p><p>In Norway, where long-term national cancer incidence data series are available, the projection of historical rates<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> (method&#x000a0;1A) resulted in a relatively good estimation of recent incidence statistics. Projections-based methods captured medium- to long-term trends reasonably but did not perform as well when there were recent changes in the trends. For example, prostate cancer rates increased by 4.3% annually in Norway between 1985 and 2008<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> but plateaued in recent years.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> Thus method&#x000a0;2, which simply applies the most recent cancer incidence rates available to recent population data, performed better than a projection of historical rates in this context (<xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>). On the other hand, lung cancer rates have uniformly increased in Norwegian women<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> in recent years, explaining the good quality of estimates based on trends for this cancer (<xref ref-type="fig" rid="F6">Fig.&#x000a0;6</xref>).</p><p>Applied to the Norwegian data, methods&#x000a0;3 and 4 were less accurate than the first two methods and underestimated the overall number of cases. They were notably less reliable for cancer sites with small numbers of deaths such as thyroid (males) or testicular cancers. Although the incidence of testicular cancer has uniformly increased in Norway over recent decades, mortality from this cancer has declined since the late-1970s, leading to low numbers of annual deaths (13 deaths nationally in 2010).<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> In this context, methods&#x000a0;3 and 4 failed to accurately estimate incident cases in age groups where deaths are rare and tend to underestimate the overall cancer burden. Furthermore, these methods also depend on the representativeness of the proxy datasets used to compute the M:I ratios on which they rely.</p><p>In GLOBOCAN 2012, method&#x000a0;5 was mainly used in the Caribbean, Latin America and some Asian countries. Applied to Norway, it performed equivalently or better than methods&#x000a0;3 and 4 in cancers with a poor prognosis such as lung or pancreatic cancer, for which the 5-year relative survival proportion in Norway is 15% and 6%, respectively, for male diagnoses 2009&#x02013;2012.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> However, the method was inadequate for cancers with good prognosis such as melanoma, breast or prostate cancers, where the 5-year relative survival rate was above 80%.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> For the latter two cancers, cure is not apparent at 5&#x000a0;years and survival proportions continue to decline in further years of follow-up,<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> thus invalidating the equation used to calculate incidence (<xref ref-type="disp-formula" rid="E1">Equation&#x000a0;1</xref>).</p><p>It is likely that method 5 combined with longer-term relative survival estimates would produce better incidence estimates for cancers with a good prognosis. In Norway, 10-year relative survival proportions for prostate and breast cancers are available and reduced to 58% and 71%, respectively.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="R18" ref-type="bibr"><sup>18</sup></xref> However, such data are less frequently available than 5-year relative survival proportions, particularly in countries were method&#x000a0;5 would be applied. In many low- and middle-income countries, where curative treatments may not be available and hence the M:I ratio is higher, the 5-year survival proportion may be a better proxy of case-fatality. For example, 5-year relative survival proportions for breast cancer in Costa Rica was 68% for diagnoses 1995&#x02013;2000<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> while the M:I ratio was 31.8% based on data from 1998&#x02013;2002,<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> indicating that method 5 would produce reliable estimates in this setting.</p><p>Because of the paucity of cancer data, national incidence in low- and middle-income countries is often estimated using datasets from regional registries or neighbouring countries. Most of the GLOBOCAN 2012 estimates for Africa and south-east Asia were based on such data (methods&#x000a0;6 to 9). Applying these methods to the Norwegian data illustrated the problem of a lack of representativeness of proxy datasets used to derive national cancer incidence. For example, method&#x000a0;7, where data from the country&#x02019;s capital city were used, provided relatively good overall estimates for Norway. In many low-income countries, the differences are likely to be considerably greater where there are marked differences in the profile of cancer in rural and urban settings. As an example, the breast cancer rate in Mumbai, India (a major urban area) was 31.0 per 100&#x02009;000 person-years in 2008&#x02013;2009, more than 2.5 times the rate observed in Barshi (12.3 per 100&#x02009;000), a rural area, in 2009&#x02013;2010.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></p><p>Producing accurate national cancer incidence estimates is a difficult task that depends on multiple factors: the availability of high-quality cancer registry data, the use of valid and reproducible estimation methods and the representativeness of proxy datasets used for calculations. Because this study was performed using high-quality cancer registry data from a high-income country, the impact of data quality issues and regional variations of the cancer burden on our results are likely to be minimal. The findings should mainly reflect the intrinsic characteristics of the different methods of estimation. On the other hand, it also means that our site- and method-specific results cannot be generalized to other countries and may not be valid in different settings. However, our study provides general conclusions regarding the context in which the different methods are likely to produce reliable estimates, provided that the required data are available.</p><p>The study provides a comparative assessment of the different methods of estimation of national incidence used in GLOBOCAN as well as some general guidance on the caveats associated with certain methods of estimation for specific cancer types. In particular, they indicate that in countries such as Norway with longstanding high quality population-based cancer registries, regional-based or trends-based estimates perform reasonably well in comparison with recorded incidence. However, such an evaluation of the validity of the estimates themselves is only possible in a few countries with high-quality national data. Elsewhere, data quality issues or a lack of national representativeness of regional datasets could potentially undermine the validity of the estimates and the evidence-based evaluation process. Assessment of uncertainty would also require additional adjustment for the completeness, accuracy and representativeness of the source information.</p><p>Along with the continuous assessment and improvements of estimation methods, efforts should be targeted at supporting the development of cancer registration worldwide. The Global Initiative for Cancer Registry Development<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> is a global partnership launched in 2011 with a goal to increase the coverage and quality of registries in low- and middle-income countries. The partnership plays a critical role in capacity-building, to attain more robust data for national and global cancer estimation purposes and aid countries in the prioritization and evaluation of national cancer control plans.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the staff of population-based cancer registries worldwide, particularly those of Denmark, Finland, Iceland, Norway and Sweden. We also thank the NORDCAN Secretariat and the members of the Section of Cancer Surveillance at IARC.</p></ack><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Soerjomataram</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Dikshit</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Eser</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mathers</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Rebelo</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.</article-title>
<source>Int J Cancer</source>. <year>2015</year>
<month>3</month>
<day>1</day>;<volume>136</volume>(<issue>5</issue>):<fpage>E359</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id><pub-id pub-id-type="pmid">25220842</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="book"><source>Global status report on noncommunicable diseases.</source>
<publisher-loc>Geneva</publisher-loc>: <collab>World Health Organization</collab>; <year>2014</year>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="book"><string-name><surname>Forman</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Brewster</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Gombe Mbalawa</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kohler</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Pi&#x000f1;eros</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<source>Cancer incidence in five continents.</source>
<volume>Volume X</volume>
<publisher-loc>Lyon</publisher-loc>: <collab>International Agency for Research on Cancer</collab>; <year>2013</year>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Larsen</surname>
<given-names>IK</given-names></string-name>, <string-name><surname>Sm&#x000e5;stuen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Johannesen</surname>
<given-names>TB</given-names></string-name>, <string-name><surname>Langmark</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Parkin</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.</article-title>
<source>Eur J Cancer</source>. <year>2009</year>
<month>5</month>;<volume>45</volume>(<issue>7</issue>):<fpage>1218</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.037</pub-id><pub-id pub-id-type="pmid">19091545</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Engholm</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Christensen</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Gjerstorff</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Klint</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>NORDCAN&#x02013;a Nordic tool for cancer information, planning, quality control and research.</article-title>
<source>Acta Oncol</source>. <year>2010</year>
<month>6</month>;<volume>49</volume>(<issue>5</issue>):<fpage>725</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.3109/02841861003782017</pub-id><pub-id pub-id-type="pmid">20491528</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="web">World population prospects: the 2012 revision [Internet]. New York: United Nations Department of Economic and Social Affairs; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://esa.un.org/unpd/wpp/index.htm">http://esa.un.org/unpd/wpp/index.htm</ext-link> [cited 2014 Dec 9].</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Loos</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>McCarron</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Weiderpass</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Hakama</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Parkin</surname>
<given-names>DM</given-names></string-name>. <article-title>Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality.</article-title>
<source>Eur J Cancer</source>. <year>2004</year>
<month>12</month>;<volume>40</volume>(<issue>18</issue>):<fpage>2794</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejca.2004.09.007</pub-id><pub-id pub-id-type="pmid">15571963</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>HR</given-names></string-name>, <string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Forman</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Mathers</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Parkin</surname>
<given-names>DM</given-names></string-name>. <article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.</article-title>
<source>Int J Cancer</source>. <year>2010</year>
<month>12</month>
<day>15</day>;<volume>127</volume>(<issue>12</issue>):<fpage>2893</fpage>&#x02013;<lpage>917</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.25516</pub-id><pub-id pub-id-type="pmid">21351269</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>M&#x000f8;ller</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Fekjaer</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hakulinen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sigvaldason</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Storm</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Talb&#x000e4;ck</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches.</article-title>
<source>Stat Med</source>. <year>2003</year>
<month>9</month>
<day>15</day>;<volume>22</volume>(<issue>17</issue>):<fpage>2751</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1002/sim.1481</pub-id><pub-id pub-id-type="pmid">12939784</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Autier</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Boniol</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Heanue</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Colombet</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Boyle</surname>
<given-names>P</given-names></string-name>. <article-title>Estimates of the cancer incidence and mortality in Europe in 2006.</article-title>
<source>Ann Oncol</source>. <year>2007</year>
<month>3</month>;<volume>18</volume>(<issue>3</issue>):<fpage>581</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1093/annonc/mdl498</pub-id><pub-id pub-id-type="pmid">17287242</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="web">Associazione Italiana Registri Tumori [Italian Association of Cancer Registries] [website]. Turin: AIRTUM; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.registri-tumori.it/">http://www.registri-tumori.it/</ext-link> [cited 2016 Jan 21].</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="web">Japanese Association of Cancer Registries [website]. Tokyo: JACR; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.jacr.info/">http://www.jacr.info/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2016 Jan 29].</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Center</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Jemal</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lortet-Tieulent</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Brawley</surname>
<given-names>O</given-names></string-name>, <etal>et al.</etal>
<article-title>International variation in prostate cancer incidence and mortality rates.</article-title>
<source>Eur Urol</source>. <year>2012</year>
<month>6</month>;<volume>61</volume>(<issue>6</issue>):<fpage>1079</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1016/j.eururo.2012.02.054</pub-id><pub-id pub-id-type="pmid">22424666</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">Engholm G, Ferlay J, Christensen N, Johannesen TB, Khan S, K&#x000f8;tlum JE, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 6.1. Copenhagen: Association of the Nordic Cancer Registries; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ancr.nu/cancer-data/">http://www.ancr.nu/cancer-data/</ext-link>. [cited 2014 Dec 9].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Lortet-Tieulent</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Renteria</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sharp</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Weiderpass</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Comber</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Baas</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988&#x02013;2010.</article-title>
<source>Eur J Cancer</source>. <year>2015</year>
<month>6</month>;<volume>51</volume>(<issue>9</issue>):<fpage>1144</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">24269041</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Ellis</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Woods</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Est&#x000e8;ve</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Eloranta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Rachet</surname>
<given-names>B</given-names></string-name>. <article-title>Cancer incidence, survival and mortality: explaining the concepts.</article-title>
<source>Int J Cancer</source>. <year>2014</year>
<month>10</month>
<day>15</day>;<volume>135</volume>(<issue>8</issue>):<fpage>1774</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.28990</pub-id><pub-id pub-id-type="pmid">24945976</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Klint</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gislum</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hakulinen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Engholm</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Tryggvad&#x000f3;ttir</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal>
<article-title>Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964&#x02013;2003 followed up until the end of 2006.</article-title>
<source>Acta Oncol</source>. <year>2010</year>
<month>6</month>;<volume>49</volume>(<issue>5</issue>):<fpage>644</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.3109/02841860903575315</pub-id><pub-id pub-id-type="pmid">20151937</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Tryggvad&#x000f3;ttir</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Gislum</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Klint</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hakulinen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Storm</surname>
<given-names>HH</given-names></string-name>, <etal>et al.</etal>
<article-title>Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964&#x02013;2003 followed up to the end of 2006.</article-title>
<source>Acta Oncol</source>. <year>2010</year>
<month>6</month>;<volume>49</volume>(<issue>5</issue>):<fpage>624</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.3109/02841860903575323</pub-id><pub-id pub-id-type="pmid">20429724</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><string-name><surname>Sankaranarayanan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Swaminathan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lucas</surname>
<given-names>E</given-names></string-name>. <source>Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan).</source>
<publisher-loc>Lyon</publisher-loc>: <collab>International Agency for Research on Cancer</collab>; <year>2011</year>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="book">Curado MP, Edwards BK, Shin HR, Storm HH, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Volume IX. Lyon: International Agency for Research on Cancer; 2007. Available from <ext-link ext-link-type="uri" xlink:href="http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/">http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Dec 14].</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Nagrani</surname>
<given-names>RT</given-names></string-name>, <string-name><surname>Budukh</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Koyande</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Panse</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Mhatre</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Badwe</surname>
<given-names>R</given-names></string-name>. <article-title>Rural urban differences in breast cancer in India.</article-title>
<source>Indian J Cancer</source>. <year>2014</year>
<season>Jul-Sep</season>;<volume>51</volume>(<issue>3</issue>):<fpage>277</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.4103/0019-509X.146793</pub-id><pub-id pub-id-type="pmid">25494122</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="web">Global Initiative for Cancer Registry Development [Internet]. Lyon: International Agency for Research on Cancer; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://gicr.iarc.fr/">http://gicr.iarc.fr/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Dec 8].</mixed-citation></ref></ref-list></back></article>